Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis
NCT05083078 · Janssen Research & Development, LLC · PHASE1 · terminated · last registry update 2022-07-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was stopped due to unanticipated feasibility constraints.” | – | Registry record, Janssen Research & Development, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL12B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-06-28Phase 3 first posted: Janssen Research & Development, LLC, Guselkumab + Guselkumab (NCT05923073)
- 2023-05-31Results posted on the registry: Sun Pharmaceutical Industries Limited, PART 1: Double-blind Placebo-controlled + PART 2: Double-blind Active Treatment Extension (NCT03897088)
- 2023-05-10Results posted on the registry: Janssen-Cilag International NV, Guselkumab + Placebo Injection (NCT03818035)
- 2023-03-24Phase 3 first posted: Eli Lilly and Company, Mirikizumab IV + Mirikizumab SC (NCT05784246)
- 2023-03-24Phase 3 first posted: Janssen Research & Development, LLC, Guselkumab + Placebo (NCT05784129)
- 2023-03-21Results posted on the registry: AbbVie, Risankizumab (NCT04102007)
- 2023-03-21Results posted on the registry: Eli Lilly and Company, Mirikizumab (NCT03556202)
- 2023-03-21Also stopped (terminated): Eli Lilly and Company, Mirikizumab (NCT03556202)
- 2023-03-14Phase 3 first posted: Eli Lilly and Company, Mirikizumab + Mirikizumab (NCT05767021)
- 2023-02-23Results posted on the registry: Sun Pharmaceutical Industries Limited, Injections of tildrakizumab (NCT03718299)
- 2023-01-03Phase 3 first posted: University of Pennsylvania, Guselkumab + Golimumab (NCT05669833)
- 2022-12-19Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Remdesivir + Risankizumab (NCT04583956)
- 2022-11-25Results posted on the registry: Eli Lilly and Company, Mirikizumab SC + Mirikizumab IV (NCT03524092)
- 2022-09-10Phase 3 first posted: Wei-Che Ko, Squaric Acid Dibutyl Ester + Dupilumab (NCT05535738)
- 2022-09-06Phase 3 first posted: Janssen Research & Development, LLC, Guselkumab Dose 1 + Guselkumab Dose 2 (NCT05528510)
- 2022-08-22Phase 3 first posted: Eli Lilly and Company, Mirikizumab (NCT05509777)
- 2022-08-11Results posted on the registry: AbbVie, Risankizumab + Placebo for risankizumab (NCT03926169)
- 2022-07-06Results posted on the registry: AbbVie, placebo for risankizumab + risankizumab IV (NCT03105128)
- 2022-06-14Results posted on the registry: AbbVie, placebo for risankizumab IV + risankizumab SC (NCT03104413)
- 2022-04-26Phase 3 first posted: Janssen-Cilag Ltd., Guselkumab + Placebo (NCT05347095)
- 2022-03-09Phase 3 first posted: Janssen Research & Development, LLC, Guselkumab + Placebo (NCT05272150)
- 2022-03-02Results posted on the registry: AbbVie, Placebo + Risankizumab (NCT03671148)
- 2022-02-28Results posted on the registry: Eli Lilly and Company, Mirikizumab + Placebo (NCT03518086)
- 2022-02-28Results posted on the registry: Eli Lilly and Company, Mirikizumab + Placebo (NCT02891226)
- 2022-02-24Results posted on the registry: AbbVie, Placebo + Risankizumab (NCT03675308)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision